[go: up one dir, main page]

TNSN06391A1 - Pyridin-4-yl-ethynyl-imidazoles et pyrazoles, antagonistes du recepteur mglur5 - Google Patents

Pyridin-4-yl-ethynyl-imidazoles et pyrazoles, antagonistes du recepteur mglur5

Info

Publication number
TNSN06391A1
TNSN06391A1 TNP2006000391A TNSN06391A TNSN06391A1 TN SN06391 A1 TNSN06391 A1 TN SN06391A1 TN P2006000391 A TNP2006000391 A TN P2006000391A TN SN06391 A TNSN06391 A TN SN06391A TN SN06391 A1 TNSN06391 A1 TN SN06391A1
Authority
TN
Tunisia
Prior art keywords
pyrazoles
imidazoles
ethynyl
pyridin
receptor antagonists
Prior art date
Application number
TNP2006000391A
Other languages
English (en)
Inventor
Bernd Buettelmann
Simona Maria Ceccarelli
Georg Jaeschke
Sabine Kolczewski
Richard Hugh Philip Porter
Paul Spurr
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2005/005559 external-priority patent/WO2005118568A1/fr
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TNSN06391A1 publication Critical patent/TNSN06391A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte: sur des dérivés de diazole de formule générale (I) dans laquelle: A, E, R1, W et R3 sont définis dans les revendications et la description, sur leur utilisation pour la préparation de médicaments traitant certaines maladies, et sur leurs procédés de préparation.
TNP2006000391A 2003-06-05 2006-11-27 Pyridin-4-yl-ethynyl-imidazoles et pyrazoles, antagonistes du recepteur mglur5 TNSN06391A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03012200 2003-06-05
PCT/EP2004/005881 WO2004108701A1 (fr) 2003-06-05 2004-06-01 Derives d'imidazole utilises comme antagonistes du recepteur du glutamate
PCT/EP2005/005559 WO2005118568A1 (fr) 2004-06-01 2005-05-23 Pyridin-4-yl-ethynyl-imidazoles et pyrazoles, antagonistes du recepteur mglur5

Publications (1)

Publication Number Publication Date
TNSN06391A1 true TNSN06391A1 (fr) 2008-02-22

Family

ID=33483899

Family Applications (2)

Application Number Title Priority Date Filing Date
TNP2005000309A TNSN05309A1 (fr) 2003-06-05 2005-12-01 Derives d'imidazole utilises comme antagonistes du recepteur du glutamate
TNP2006000391A TNSN06391A1 (fr) 2003-06-05 2006-11-27 Pyridin-4-yl-ethynyl-imidazoles et pyrazoles, antagonistes du recepteur mglur5

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TNP2005000309A TNSN05309A1 (fr) 2003-06-05 2005-12-01 Derives d'imidazole utilises comme antagonistes du recepteur du glutamate

Country Status (38)

Country Link
US (3) US7332510B2 (fr)
EP (1) EP1636206B1 (fr)
JP (1) JP4401384B2 (fr)
KR (1) KR100778948B1 (fr)
CN (1) CN100408572C (fr)
AR (1) AR044478A1 (fr)
AT (1) ATE377008T1 (fr)
AU (1) AU2004245208B2 (fr)
BR (1) BRPI0411095B8 (fr)
CA (1) CA2527315C (fr)
CL (1) CL2004001347A1 (fr)
CR (1) CR8094A (fr)
CY (1) CY1107856T1 (fr)
DE (1) DE602004009796T2 (fr)
DK (1) DK1636206T3 (fr)
EA (1) EA010577B1 (fr)
EC (1) ECSP056202A (fr)
ES (1) ES2294504T3 (fr)
GT (1) GT200400117A (fr)
HN (1) HN2004000208A (fr)
HR (1) HRP20070529T3 (fr)
IL (1) IL171930A (fr)
MA (1) MA27881A1 (fr)
MX (1) MXPA05013149A (fr)
MY (2) MY137272A (fr)
NO (1) NO332143B1 (fr)
NZ (1) NZ543637A (fr)
PA (1) PA8604101A1 (fr)
PE (1) PE20050162A1 (fr)
PL (1) PL1636206T3 (fr)
PT (1) PT1636206E (fr)
RS (1) RS53183B (fr)
SI (1) SI1636206T1 (fr)
TN (2) TNSN05309A1 (fr)
TW (1) TWI338007B (fr)
UA (1) UA80888C2 (fr)
WO (1) WO2004108701A1 (fr)
ZA (2) ZA200509807B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
US7452909B2 (en) 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
NZ551253A (en) * 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
PT2125779T (pt) * 2006-12-21 2016-07-19 Hoffmann La Roche Polimorfos de um antagonista de um recetor de mglur5
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
MX2013010698A (es) 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
UA114529C2 (uk) * 2012-10-18 2017-06-26 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як модулятори активності рецептора mglur5
EP2909178B1 (fr) * 2012-10-18 2016-10-05 F. Hoffmann-La Roche AG Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5
CA3018375A1 (fr) * 2016-03-30 2017-10-05 Carin Sjolund Modulateurs allosteriques negatifs de mglur5 utiles dans le traitement de lesions du cerveau mature
WO2021110574A1 (fr) * 2019-12-02 2021-06-10 F. Hoffmann-La Roche Ag Inhibiteurs d'alcynyle- (hétéroaryl)-carboxamide hcn1
KR20230027145A (ko) 2020-06-05 2023-02-27 노에마 파르마 아게 결절성 경화증 복합증의 치료 방법
TW202220649A (zh) * 2020-07-30 2022-06-01 瑞士商諾埃瑪製藥公司 三叉神經痛之治療方法
EP4658268A1 (fr) 2023-02-02 2025-12-10 Noema Pharma AG Méthodes de traitement du syndrome de dravet

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508560A (en) * 1981-11-11 1985-04-02 Ciba Geigy Corporation Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
AU780009B2 (en) * 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
MXPA03004862A (es) * 2000-12-04 2005-02-14 Hoffmann La Roche Derivados de feniletenilo o feniletinilo como antagonistas del receptor de glutamato.
AU2002360621B2 (en) * 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
WO2004038374A2 (fr) * 2002-10-24 2004-05-06 Merck & Co., Inc. Derives d'alcyne utilises comme marqueurs pour la liaison au recepteur du glutamate metabotropique
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives

Also Published As

Publication number Publication date
DE602004009796T2 (de) 2008-08-28
HN2004000208A (es) 2009-02-03
US20080119489A1 (en) 2008-05-22
CN1802367A (zh) 2006-07-12
ZA200609681B (en) 2008-06-25
DE602004009796D1 (de) 2007-12-13
JP4401384B2 (ja) 2010-01-20
JP2006526588A (ja) 2006-11-24
BRPI0411095B8 (pt) 2021-05-25
AU2004245208A1 (en) 2004-12-16
AR044478A1 (es) 2005-09-14
KR20060057537A (ko) 2006-05-26
US20080103306A1 (en) 2008-05-01
WO2004108701A1 (fr) 2004-12-16
TNSN05309A1 (fr) 2007-07-10
PT1636206E (pt) 2008-01-28
EA200501887A1 (ru) 2006-10-27
IL171930A0 (en) 2006-04-10
HRP20070529T3 (hr) 2008-05-31
EP1636206A1 (fr) 2006-03-22
CY1107856T1 (el) 2013-06-19
RS20050892A (sr) 2007-12-31
GT200400117A (es) 2005-02-07
CN100408572C (zh) 2008-08-06
CR8094A (es) 2006-05-30
TWI338007B (en) 2011-03-01
NO332143B1 (no) 2012-07-02
MY137272A (en) 2009-01-30
SI1636206T1 (sl) 2008-02-29
IL171930A (en) 2010-12-30
US7973165B2 (en) 2011-07-05
TW200509920A (en) 2005-03-16
US20040248888A1 (en) 2004-12-09
ES2294504T3 (es) 2008-04-01
DK1636206T3 (da) 2008-02-11
NO20055465L (no) 2005-11-18
AU2004245208B2 (en) 2007-04-26
US8481548B2 (en) 2013-07-09
BRPI0411095A (pt) 2006-07-18
EP1636206B1 (fr) 2007-10-31
US7332510B2 (en) 2008-02-19
KR100778948B1 (ko) 2007-11-28
HK1093070A1 (zh) 2007-02-23
MA27881A1 (fr) 2006-05-02
EA010577B1 (ru) 2008-10-30
PL1636206T3 (pl) 2008-04-30
CA2527315C (fr) 2010-08-10
ATE377008T1 (de) 2007-11-15
NZ543637A (en) 2008-04-30
RS53183B (sr) 2014-06-30
BRPI0411095B1 (pt) 2018-04-03
ECSP056202A (es) 2006-04-19
CL2004001347A1 (es) 2005-05-06
CA2527315A1 (fr) 2004-12-16
UA80888C2 (en) 2007-11-12
MXPA05013149A (es) 2006-03-17
ZA200509807B (en) 2006-12-27
MY143353A (en) 2011-04-29
PE20050162A1 (es) 2005-03-22
PA8604101A1 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
TNSN06391A1 (fr) Pyridin-4-yl-ethynyl-imidazoles et pyrazoles, antagonistes du recepteur mglur5
TNSN01122A1 (fr) Composes heterocycliques comme coordonnats du recepteur gabaa
MA28110A1 (fr) Antagonistes du recepteur d'acetylcholine muscarinique
EP1467730A4 (fr) Ligands non steroidiens pour le recepteur des corticoides, compositions et utilisations desdits ligands
DE60130675D1 (de) Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
TNSN01148A1 (fr) Agonistes des recepteurs beta 3-adrenergiques, et compositions, les contenant.
DK1328269T4 (da) Kombination af en CB1-receptorantagonist og sibutramin til behandling af fedme
DE602004011358D1 (de) (4-hydroxyphenyl)-1h-indol-3-carbaldehydoxim-derivative als östrogenagentien
GB0504828D0 (en) Therapeutic agents
TNSN06210A1 (fr) Nitro-oxydérivés de prostaglandines
TNSN06369A1 (fr) Derives de tetrahydronaphtyridine utiles comme ligands du recepteur d'histamine h3
DE60027467D1 (de) Verbesserte handwaschvorrichtung
TNSN06188A1 (fr) Derives de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de recepteurs de chimiokines
TNSN02015A1 (fr) Composes nouveaux antagonistes de ppar, et compositions les contenant
TNSN06037A1 (fr) Formulations liquides
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
SG164283A1 (en) New benzimidazole derivatives
MA27900A1 (fr) Antagonistes du recepteur de l'acetylcholine muscarinique
MA27901A1 (fr) Antagonistes du recepteur de l'acetylcholine muscarinique
MA27973A1 (fr) Antagonistes du recepteur de l'acetylcholine muscarinique
TNSN01175A1 (fr) Derives de piperidines antagonistes selectives de sous- types de recepteurs de nmda, et compositions les contenant.
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
MA28109A1 (fr) Antagonistes du recepteur acetylcholine muscarinique
FR2860427B1 (fr) Insert humeral pour une prothese d'epaule inversee.
TR200400424T4 (tr) IOP'nin kontrolü ve glokom tedavisi için 5HT2 agonistleri